Welcome to our dedicated page for BVXV news (Ticker: bvxv), a resource for investors and traders seeking the latest updates and insights on BVXV stock.
BiondVax Pharmaceuticals Ltd. (BVXV) is a clinical-stage biopharmaceutical company pioneering universal influenza vaccines and novel immunotherapies. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, research breakthroughs, and regulatory milestones.
Access official press releases and curated news coverage spanning clinical trial progress, strategic partnerships, and financial updates. Our comprehensive aggregation ensures you stay informed about BVXV's innovative vaccine pipeline and its position within the competitive biotech landscape.
Key focus areas include updates on universal vaccine candidates, preclinical research advancements, and collaborations with scientific institutions. All content is rigorously verified to maintain factual accuracy while avoiding speculative analysis.
Bookmark this page for streamlined access to essential BVXV developments. Check regularly for authoritative updates supporting informed decision-making in the dynamic biopharmaceutical sector.
The U.S. influenza vaccines market was valued at US$ 3,962 million in 2022 and is projected to reach US$ 8,347 million by 2031, witnessing a CAGR of 8.6%. This growth is driven by increasing R&D, the launch of quadrivalent vaccines, an aging population, and heightened vaccine awareness. The U.S. remains the largest influenza vaccines market globally. Key market participants include BiondVax Pharmaceuticals (BVXV), Novavax, and GSK, among others. The report provides insights into market dynamics, vaccination trends, pricing analysis, and regulatory frameworks from 2018 to 2031. Additionally, the ongoing COVID-19 pandemic is expected to further drive demand for influenza vaccines.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) reported its full-year financial results for 2022, revealing a net loss of $5.8 million compared to $8.2 million in 2021. Key developments included an increase in R&D expenses to $5.7 million from $3.2 million and a reduction in marketing, general, and administrative expenses to $5.3 million from $7.6 million. The company reported total operating expenses of $11.06 million, up from $10.8 million in 2021, while financial income rose to $5.2 million from $2.6 million, largely due to currency exchange benefits. As of December 31, 2022, BiondVax had cash reserves of $14 million, down from $17.3 million in 2021. The company is advancing its pipeline of nanosized VHH antibodies (NanoAbs) and plans to focus on clinical trials for COVID-19 therapies while managing the risks posed by evolving virus variants.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced that CEO Amir Reichman will present at the 17th annual BIO-Europe Spring from March 20-22, 2023, in Basel, Switzerland. This major biotech conference expects over 2,800 executives and 15,000+ one-on-one meetings. Reichman's presentation on March 21 at 11:30 a.m. will highlight successful preclinical in vivo results of BiondVax's innovative inhaled COVID-19 treatment and upcoming plans for nanosized VHH-antibodies aimed at treating autoimmune diseases like psoriasis and asthma. BiondVax's robust R&D strategy emphasizes developing a pipeline of effective treatments addressing significant medical needs.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced that CEO Amir Reichman will present at the BIO CEO & Investor Conference from Feb. 6-9, 2023, in New York. The presentation will highlight recent successful preclinical in vivo results for BiondVax's inhaled COVID-19 treatment and the development of nanosized VHH-antibodies (NanoAbs) targeting autoimmune diseases like psoriasis and asthma. The company aims to create a pipeline of innovative products addressing underserved medical needs. Attendees are encouraged to schedule meetings with BiondVax leaders at the conference.
BiondVax Pharmaceuticals (Nasdaq: BVXV) announced promising results from a preclinical study on its inhaled anti-COVID-19 treatment, utilizing nanosized antibodies (NanoAbs). In hamsters, those treated with NanoAbs exhibited over 30 times lower lung viral titers compared to a placebo group, suggesting significant efficacy. The study also showed that treated animals experienced milder illness and faster recovery. A Phase 1/2a clinical trial is set to begin in late 2023, aiming to develop this therapy for COVID-19 and other diseases with high unmet medical needs, such as psoriasis and asthma.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced that CEO Amir Reichman will present at the Biotech Showcase conference from January 9-11, 2023, in San Francisco. The presentation, scheduled for January 9 at 9:30 a.m. PT, will cover successful preclinical trial results of BiondVax's inhaled COVID-19 therapy and plans for a nanosized antibody (NanoAb) pipeline targeting autoimmune diseases. This opportunity aims to highlight BiondVax’s innovative approach in addressing unmet medical needs. For one-on-one meetings, interested parties can use the Biotech Showcase partnering platform.
BiondVax Pharmaceuticals (Nasdaq: BVXV) released a letter from CEO Amir Reichman detailing 2022 milestones and future objectives. Key achievements include successful preclinical results for an inhaled COVID-19 NanoAb therapy and significant financing efforts. The company entered collaborations with Max Planck Institute and University Medical Center Göttingen to develop innovative nanosized antibodies, targeting unmet medical needs. BiondVax aims to initiate Phase 1/2a clinical trials for the COVID-19 therapy in late 2023, supported by a robust funding strategy.
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has completed an $8 million underwritten public offering, with Aegis Capital Corp. serving as the sole bookrunner. The company, headquartered in Jerusalem, focuses on developing treatments for infectious diseases and has collaborations for COVID-19 nanosized antibody (NanoAb) development. BiondVax aims to commercialize NanoAbs for various diseases. This funding is expected to support its research and development efforts.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) has successfully closed an underwritten public offering, raising $8 million in gross proceeds. The offering includes 1,600,000 units, where each unit consists of one American Depositary Share (ADS) and two warrants. Each ADS represents 400 ordinary shares. The company plans to deploy the net proceeds towards the advancement of its NanoAbs development program and general corporate purposes. Aegis Capital Corp. served as the sole book-running manager for this offering.
